FDA has awarded the first three co-discovery of the new drug quizartinib breakthrough therapy
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
AML is a malignant blood and bone marrow cancer that causes abnormally dysfunctional cancerous white blood cells in the patient's body to grow and accumulate uncontrolledly and affect the production of normal blood cellstoday,, the first third-
company, announcedthe
of the FDA, which has granted it theof new drugs to beQuizartinibQuizartinib is a FLT3 inhibitor under research for the treatment of adult patients with recurrent/incurable FLT3-ITD acute myeloid leukemia (AML)This confirmation will accelerate the research and development of quizartinib, which is expected to bring new drugs to patients at an early dateapproval for this breakthrough therapy is based on the key phase 3 clinicaltrialof quizartinib, which was published at the
23rdCongress of the European Society of Hematology in June 2018QuANTUM-R is a key global, open label, randomized phase 3 study, and the results of the trial show that oral-specific FLT3 inhibitor quizartinib monotherapy extends the total survival of patients with recurrent/incurable FLT3-ITD acute myeloid leukemia compared to chemotherapyQuANTUM-R shows the same safety as the clinical development program of quizartinib
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
